These findings highlight the necessity of a specific, robust, fully-automated PD-L1 IHC assay to be used in patient selection for clinical trials and to identify additional tumor types that may benefit from targeted PD-L1/PD-1 immunotherapy. This evidence concerns the gene CD274 and neoplasm.